Original research

Women and men exhibit distinct gut microbial profiles linked to colorectal cancer development

Bucher-Johannessen, C. [1,2,3], Kværner, AS.[4]*, Birkeland, E.[5], Botteri E.[2,4], Avershina, E.[1,5], Bemanian, V.[6], Hoff, G.[4,7], Randel, KR.[4], Hovig, E.[1,3], Berstad, P.[4], Rounge, TB.[1,4,5]*

**Shared first authorship*

Author Affiliations:

1 Department of Tumour Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway

2 Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway

3 Department of Informatics, University of Oslo, Oslo, Norway

4 Department of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health; Oslo, Norway

5 Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway

6 Department of Pathology, Akershus University Hospital, Lørenskog, Norway

7 Department of Research, Telemark Hospital, Skien, Norway

Corresponding Authors

Ane Sørlie Kværner

Tel: +47 901 157 47

Mailing address: Cancer Registry of Norway, Norwegian Institute of Public Health, Postboks 5313 Majorstuen, 0304 Oslo, Norway

E-mail address: a.s.kvarner@gmail.com

ORCID identifier: 0000-0001-6247-7304

Trine B. Rounge

Tel: +47 996 043 04

Mailing address: University of Oslo, Postbox 1068 Blindern, 0316 Oslo, Norway

E-mail address: trinro@uio.no

ORCID identifier: 0000-0003-2677-2722

Sources of Support

This project was made possible by funding from the Norwegian Cancer Society (grant nos. 190179 and 198048), the Norwegian Cancer Society's umbrella organization for cancer research ("Kreftforeningens paraplystiftelse for kreftforskning"), the Research Council of Norway (grant no. 280667), and the South-Eastern Norway Regional Health Authority (grant nos. 2022067 and 2020056). The BCSN trial study was funded by the Norwegian Parliament (Norwegian national budget from 2011). The bowel preparation used for colonoscopy was provided free of charge by Ferring Pharmaceuticals. The funders had no role in study design, data collection, analysis, interpretation, or the writing of this article.

Short running head: Sex, the gut microbiome and colorectal cancer

48

49 **Abbreviations**

50 ACME: Average causal mediation effect

51 ADE: Average direct effect

52 AICR: American Institute for Cancer Research

53 ANOVA: Analysis of variance

54 ASV: Amplicon sequence variant

55 BCSN: Bowel Cancer Screening in Norway

56 BH: Benjamini-Hochberg

57 BMI: Body mass index

58 CI: Confidence interval

59 CRC: Colorectal cancer

60 FFQ: Food frequency questionnaire

61 FIT: Fecal immunochemical test

62 GO: Gene ontology

63 KBS: Kostberegningssystem

64 MaAsLin: Microbiome multivariable associations with linear models

65 NCT: National clinical trial

66 OR: Odds ratio

67 PCoA: Principal coordinate analysis

68 PERMANOVA: Permutational multivariate analysis of variance

69 PPV: Positive predictive value

70 SD: Standard deviation

71 TE: Total effect

72 TSS: Total sum scaling

73 WCRF: World Cancer Research Fund

74

75 **Trial Registration:** The BCSN is registered at clinicaltrials.gov (National clinical trial
76 (NCT) no. 01538550).

Abstract

Background: The gut microbiome has emerged as a promising source of biomarkers to enhance early detection of colorectal cancer (CRC). However, sex-specific differences in gut microbial profiles and their relationship to CRC risk remain underexplored.

Objective: To investigate sex differences in screening-detected colorectal lesions and gut microbial profiles, as well as the potential for sex-specific associations between the gut microbiome and colorectal lesions.

Methods: This cross-sectional study included 1,034 faecal immunochemical test-positive screening participants aged 55–77 years recruited from the Norwegian CRCbiome study. Shotgun metagenomic sequencing was used to generate taxonomic and functional profiles of the gut microbiome, which were integrated with clinicopathological, demographic, and lifestyle data. Associations between sex, colorectal lesions, and microbial characteristics – including α-diversity, β-diversity, and abundances of bacterial species and functions – were assessed, including their interactions.

Results: Male participants had significantly higher odds of presenting with both non-advanced (OR: 1.50; 95% CI: 1.00–2.26) and advanced (OR: 1.46; 95% CI: 1.10–1.93) colorectal lesions compared to women. Gut microbial profiles differed markedly by sex, demonstrating compositional shifts and distinct bacterial profiles (19 taxa and 58 functions more abundant in men, 13 bacteria and 41 functions more abundant in women). In women, microbial α-and β-diversity varied across lesion subtypes, whereas no such differences were observed in men. Interaction analyses identified 5 bacteria and 6 functions that were differentially associated with colorectal lesions by sex.

Conclusion: This study highlights sex-specific differences in the gut microbiome and their association with colorectal lesions, emphasising the need to take sex into account in future research aiming to enhance CRC prevention strategies and treatment.

Keywords: Sex, gut microbiome, effect modification, mediation, colorectal lesions, colorectal cancer, colorectal cancer screening

Introduction

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide (1). Both CRC incidence and mortality show a male predominance, a pattern which remains consistent across countries, despite significant variations in incidence rates (2, 3). Variations in exposure to, and effects of, dietary and lifestyle factors are likely contributors to the observed disparities (4); however, the extent of their contribution remains unclear. Projections suggest that the observed sex disparities in CRC risk are likely to persist in the coming decades (2).

CRC screening has the potential to reduce both CRC incidence (5-8) and mortality (5-12). Faecal immunochemical testing (FIT) is the most widely used screening method (13), and is recommended as the preferred test by EU guidelines (14). FIT detects haemoglobin in stool, with positivity thresholds varying from >10 to >150 µg/g across European screening programs (15), prompting follow-up diagnostic colonoscopy. While FIT has a good sensitivity for colorectal cancers (16), it is less accurate for precancerous lesions (16) and lesions located in the proximal colon (17). Additionally, FIT-based screening has been criticised for potentially disadvantaging women (18). This may be due to anatomical, physiological, and/or pathogenetic differences affecting diagnostic performance of either the FIT (19-23) or the colonoscopy (24-27). Complementary strategies to improve screening efficacy and equity are needed.

Emerging evidence supports a role of the gut microbiome in CRC development (28-33). Proposed mechanisms include interaction with the immune system (34-36), induction of inflammation and oxidative stress (37-39), cross-talk with the endocrine system (40-42), and production of bioactive compounds, including metabolites, toxins, and virulence factors (43-49). A growing number of studies suggest that specific microbes — alone or in combination with other biomarkers — can be used to predict colorectal lesions (50, 51). As sex impacts the microbial profile (52-55), it is plausible that the microbiome's role in CRC development, as well as its potential as a biomarker

129 source, varies by sex. While there is some evidence supporting this hypothesis (56-63), existing
130 studies are either limited by reliance on mouse models (57, 60, 64, 65) or insufficient sample sizes
131 (58, 61, 63) and/or lack of control for dietary and lifestyle exposures (56, 58, 59, 61-63) – important
132 predictors of both CRC risk (66, 67) and microbial variation (68, 69).
133 To enhance our understanding of the potential interactions between sex and the gut microbiome
134 in CRC development, we analysed data from a large CRC screening study in Norway, combining
135 metagenomic taxonomic and functional profiles with comprehensive clinicopathological, lifestyle,
136 and demographic information. Specifically, our objectives were to i) identify differences between
137 men and women in a) the prevalence of screen-detected colorectal lesions and b) gut microbial
138 profiles, controlling for lifestyle and demographic factors, and ii) explore potential pathways
139 through which these factors may interact.

140 # Methods and materials

141 ## Study population

142 In this study, we used data from the CRCbiome study, which has been described in detail
143 previously (70). The CRCbiome study was initiated in 2017 and invited participants from the large
144 Bowel Cancer Screening in Norway pilot trial (BCSN) (n=139,291) (71). The BCSN started in
145 2012, where Norwegian citizens from selected municipalities surrounding the capital of Oslo
146 (aged 50-74 years) were invited to either undergo once-only sigmoidoscopy or FIT test biennially.
147 The CRCbiome study recruited participants from the FIT arm (rounds 2-4), using a positive FIT
148 test as an inclusion criterion (≥15 µg haemoglobin/g faeces). Participants with a positive FIT test
149 were referred to colonoscopy, where potential neoplastic lesions were removed. Participants were
150 asked to fill in a lifestyle and demographic questionnaire (LDQ) and a food frequency
151 questionnaire (FFQ) prior to the scheduled colonoscopy. Return of either questionnaire provided
152 consent and enrolment into the study. Samples were excluded from analyses if they had
153 insufficient sequencing depth, defined as less than 1 gigabase of sequencing output after quality
154 control. Additionally, samples were excluded if the individuals did not attend follow-up
155 colonoscopy or presented with one or two non-advanced neoplastic lesions or serrated lesions
156 during screening.
157 The BCSN trial and the CRCbiome study have been approved by the Regional Committee for
158 Medical and Health-related Research Ethics in Southeast Norway (REK ref: 2011/1272 and
159 63148, respectively. The BCSN trial is registered at clinicaltrials.gov (Clinical Trial (NCT) no.:
160 01538550).

161 ## Outcome measures

162 In this study, participants were classified into three colonoscopy groups: 1) “No neoplasia”,
163 including individuals without lesions, those with ≥1 non-neoplastic lesion (e.g., inflammatory or

164 granulation tissue polyps), and those with other findings (e.g., diverticulitis, haemorrhoids, or IBD);
165 2) “Non-advanced neoplastic lesions, and 3) “Advanced lesions”, which included those with ≥1
166 advanced serrated lesion, ≥1 advanced adenoma, or CRC. Advanced adenoma was defined as
167 any adenoma with at least one of the following characteristics: villous histology (≥25% villous
168 components), high-grade dysplasia, or a polyp size ≥10 mm. Advanced serrated lesions were
169 defined as serrated lesions with a size ≥10 mm or evidence of dysplasia. CRC was classified as
170 the presence of adenocarcinoma originating in the colon or rectum.

171 Questionnaire data

172 Lifestyle and demographic information was collected using a self-administered four-page
173 questionnaire, described in detail elsewhere (70). The questions relevant to the current study
174 captured data on demographic factors (national affiliation, education, employment status, and
175 marital status), clinical factors (family history of CRC and diagnosis of chronic bowel disorders),
176 and lifestyle factors (smoking and snus habits, and physical activity level).
177 Dietary intake data were obtained using a validated 14-page semi-quantitative FFQ, developed
178 and validated at the Department of Nutrition, University of Oslo (72-77). This FFQ assessed
179 habitual dietary intake over the preceding year and provided estimates of total energy intake,
180 macronutrient and micronutrient intake, as well as intake of foods and beverages (256 in total).
181 Dietary intake in grams per day was calculated using the dietary calculation system KBS (short
182 for “**K**ost**b**eregnings**s**ystem”). The most recent database at the time (AE-18) was used, which is
183 an extended version of the 2018 Norwegian Food Composition Table (78).

184 The FFQ also recorded self-reported body weight (kg) and height (cm), which were used to
185 calculate body mass index (BMI).
186 Based on data from the two questionnaires, a seven-point diet and lifestyle score was created to
187 measure adherence to the 2018 World Cancer Research Fund (WCRF)/American Institute for

188 Cancer Research (AICR) cancer prevention recommendations. The recommendations were
189 operationalised using a standardised scoring system developed by Shams-White *et al*. (79, 80),
190 as described in detail elsewhere (81).

191 **Sample collection and DNA extraction**

192 The FIT tests were collected at home by the participants and sent by mail to the testing facility.
193 For DNA extraction, leftover FIT samples were buffered, and 500 µL aliquots were used for
194 analysis. DNA extraction utilised the QIAsymphony DSP Virus/Pathogen Midikit (Qiagen, Hilden,
195 Germany), according to the instruction manual, with additional off-board lysis and bead-beating.
196 Extracted DNA was buffered in 60 µl AVE buffer. DNA from FIT tubes show no detectable cross-
197 contamination and harbours diverse microbial communities (82, 83).

198 **Library preparation and sequencing**

199 Following extraction, sample quality was measured on a NanoDrop 2000 spectrophotometer
200 (Thermo Fisher Scientific, MA, USA) and DNA concentration using a Qubit Fluorometer (Thermo
201 Fisher Scientific, MA, USA). Samples with a DNA concentration above 0.7 ng/µl were considered
202 eligible for library preparation and sequencing. Library preparation was performed using the
203 Nextera DNA Flex Library Prep Reference Guide according to the manual with the modification
204 of reducing reaction volume to one-fourth of the reference. Sample pools were sequenced on the
205 Illumina NovaSeq system (Illumina Inc., CA, USA), resulting in paired-end 151 bp reads. Library
206 preparation and sequencing were performed at the FIMM Technology Centre in Helsinki, Finland.

207 **Bioinformatics**

208 Sequencing reads were quality controlled using KneadData (v0.12)
209 (http://huttenhower.sph.harvard.edu/kneaddata) with default settings to remove adapters, low-
210 quality bases and reads mapping to the human genome. MetaPhlAn4 (84) (v4.0.6) was used to

211 identify the relative abundance of microbial taxa and bacterial taxa for use in subsequent
212 analyses. Further, HumanN3 was used (85) (v3.7) to determine gene content using the
213 mpa_vOct22_ChocoPhlAn_202212 pangenome database and the UniRef90 (86) database for
214 classifying the gene families into Gene Ontology (GO) annotations (87, 88) covering biological
215 processes, molecular functions and cellular components – hereafter collectively referred to as
216 functions. Abundance of gene content from HumanN3 was scaled by the number of quality-
217 assessed reads per million.

218 **Statistics**

219 We summarised continuous variables using the median value with interquartile range and
220 categorical variables using counts with percentages. Within-group differences were examined
221 using Kruskal-Wallis or Wilcoxon rank sum test for continuous variables and Pearson`s Chi-
222 squared or Fisher`s exact test for categorical variables, as appropriate.
223 To ensure complete datasets, multivariate imputation by chained equations was performed using
224 the R package *mice* (89). The imputed variables included marital status, employment status,
225 smoking status and the WCRF/AICR score. All variables listed in Table 1 were used as predictors
226 in the imputation process. All analyses reported in the manuscript are based on the imputed
227 dataset.
228 We ran a multinomial logistic regression analysis to study the association between sex and
229 colonoscopy findings (i.e., a) no neoplasia (reference category); b) non-advanced neoplastic
230 lesions; and c) advanced lesions). The analysis was adjusted for the following covariates: Model
231 1) age (continuous) and screening centre (centre 1, centre 2); model 2: model 1 covariates,
232 employment status (employed, retired, other), marital status (not married/non-cohabiting,
233 married/cohabiting), smoking status (never smoked, ever smoked) and the WCRF/AICR score
234 (continuous). Covariates were selected based on the association patterns observed in **Table 1**

235 and **Supplementary Table 1**. Unless otherwise specified, the subsequent analyses were
236 conducted using these covariate sets.
237 To investigate microbial differences between sexes, α-diversity, β-diversity, and differential
238 abundance of bacterial species and functions were assessed. Differences in α-diversity indices
239 (Shannon and Inverse Simpson) were analysed using analysis of variance (ANOVA). β-diversity
240 differences were assessed using the Bray-Curtis dissimilarity index, calculated with the vegdist
241 function in the R package *vegan* (90) and tested for significance using permutational analysis of
242 variance (PERMANOVA) with 999 permutations. Differentially abundant taxa and functions were
243 identified using *MaAsLin2* (91) with the following settings: a minimum abundance threshold of
244 10%; log2 transformation with zero values replaced by a pseudo-count equal to half the lowest
245 observed value across all features; normalisation set to none for bacterial abundances and total
246 sum scaling for functions; and a linear model. Prior to analysis, functions strongly correlated with
247 bacterial species (Spearman's correlation coefficient > 0.5) were excluded to mitigate the risk of
248 spurious associations driven by bacterial variation. P-values were adjusted for multiple testing
249 using the Benjamini-Hochberg (BH) correction method.
250 To investigate whether the gut microbiome mediated the association between sex and colorectal
251 lesions, a causal mediation analysis was performed following the approach described by Kværner
252 *et al.* (92). A sex-associated microbial score was developed to represent the influence of sex on
253 the gut microbiome. Two versions of the microbial score were developed based on differential
254 abundance analyses: one minimally adjusted score, allowing differences in lifestyle and
255 demography between sexes to contribute to microbial variation, and another fully adjusted score.
256 The scores were calculated as the log-transformed ratios of the summed abundances of microbial
257 species positively associated with sex to the summed abundances of species negatively
258 associated with sex. To reduce bias, a five-fold cross-validation approach was used for generation
259 of the scores, where for each subset, the microbial scores were derived using the microbial
260 species identified as significantly associated with sex in the remaining subsets. In the mediation

261 analysis, sex was treated as the independent variable, colorectal lesions as the outcome, and the
262 sex-associated microbial score as the mediator. To enhance statistical power, non-advanced
263 neoplastic lesions were grouped with advanced lesions. The analysis was adjusted for the same
264 set of covariates as in model 2, along with the cross-validation partition identity to account for
265 variability introduced by the score development process. Mediation effects were estimated using
266 the R package *mediation* (93) and the function mediate. This involved fitting two models: 1) a
267 multivariate linear regression model to assess the association between sex and the sex-
268 associated microbial score, and 2) a generalised linear model to evaluate the association between
269 the sex-associated microbial score and colorectal lesions, controlling for sex. We report point
270 estimates and non-parametric bootstrap confidence intervals using 1,000 bootstrap simulations.
271 To validate these findings, an alternative mediation analysis was performed using the R package
272 *medflex* (94) and the function neModel. This approach relies on a natural effects model with
273 imputation of nested counterfactuals, ensuring that the mediation effects are robust and not
274 dependent on specific covariate levels.
275 To investigate sex-specific influences of the gut microbiome on colorectal lesions, sex-stratified
276 analyses were conducted for α-diversity, β-diversity, and differential abundance of microbial taxa
277 and functions. Interactions were examined using the entire dataset. For α- and β-diversity, sex-
278 specific associations were examined by including interaction terms for sex and lesion status.
279 Bacterial species and functions that were differently abundant in advanced lesions at a BH-
280 corrected p-value of 0.2 and 0.15, respectively, in either men or women, were further analysed
281 for interaction effects in the entire dataset using multinomial logistic regression, including
282 interaction terms of sex and the log-transformed abundance values.
283 To address potential disparities in the distribution of lesion subtypes between men and women,
284 stratified analyses were conducted comparing individuals with advanced serrated lesions to those
285 without any neoplasia. Analyses were also performed without the inclusion of the less common
286 advanced serrated lesions.

287 All analyses were performed using the R statistical environment with the main packages *tidyverse*

288 (95) (v1.3.1), *rstatix* (96) (v0.7.0), *nnet* (97) (v7.3-16), *mice* (89) (v3.14.0), *vegan* (90) (v2.5.7),

289 *MaAsLin2* (91) (v1.12.0), *mediation* (93) (v4.5.0) and *medflex* (94) (v0.6-7).

290 The significance level was set to $p < 0.05$ for all analyses.

Results

Characteristics of the study population overall and by sex

Participants' characteristics overall and stratified by sex are presented in Table 1. The study included more men (n=582; 56%) than women (n=452; 44%). Men were more likely to be married, possess a university degree, and be employed, whereas women more frequently reported bowel disorders. In terms of lifestyle factors, men were more likely to use tobacco snus, have a higher BMI, and lower adherence to cancer prevention recommendations compared to women. No difference in lesion location (proximal versus distal) was observed between men and women. However, there was a significant difference in lesion subtypes, women more often presenting with advanced serrated lesions than men. In both sexes, the presence of screen-detected lesions (whether non-advanced or advanced) was associated with older age, being retired, being unmarried or not cohabiting, being screened at Bærum Hospital and having a higher alcohol consumption (Supplementary Table 1).

Table 1. Participants characteristics overall (n=1,034) and among women (n=452) and men (n=582)[1].

Variables	**n**	**Female**[1] **(n = 452)**	**Male**[1] **(n = 582)**	**Overall**[1] **(n = 1,034)**	**p-value**[2]
Age, years	1,034	67 (62, 72)	67 (62, 72)	67 (62, 72)	0.901
Screening center, n (%)	1,034				0.830
Moss		250 (55)	318 (55)	568 (55)	
Bærum		202 (45)	264 (45)	466 (45)	
National affiliation, n (%)	989				0.285
Norwegian		415 (94)	504 (92)	919 (93)	
Non-norwegian		27 (6.1)	43 (7.9)	70 (7.1)	
Family history of CRC, n (%)	923	87 (21)	98 (19)	185 (20)	0.506
Localisation	584				0.821
Distal only		61 (26)	89 (25)	150 (26)	
Any proximal		170 (74)	264 (75)	434 (74)	
Advanced serrated lesions	584				**0.031**
Yes		60 (26)	64 (18)	124 (21)	
No		171 (74)	289 (82)	460 (79)	
Marital status, n (%)	1,013				**<0.001**
Not married/non-cohabiting		121 (27)	81 (14)	202 (20)	

Married/cohabiting		326 (73)	485 (86)	811 (80)	
Education, n (%)	1,008				**0.021**
Primary school		102 (23)	94 (17)	196 (19)	
High school		174 (39)	219 (39)	393 (39)	
University/college		168 (38)	251 (45)	419 (42)	
Employment status, n (%)	1,015				**0.002**
Employed		119 (27)	203 (36)	322 (32)	
Retired		259 (58)	307 (54)	566 (56)	
Other		69 (15)	58 (10)	127 (13)	
Bowel disorder, n (%)	1,002				**0.001**
No bowel disease		357 (82)	501 (89)	858 (86)	
Any disorder		81 (18)	63 (11)	144 (14)	
Smoking status, n (%)	1,013				0.384
Never smoked		173 (39)	204 (36)	377 (37)	
Ever smoked		274 (61)	362 (64)	636 (63)	
Snus status, n (%)	971				**<0.001**
Non snuser		412 (99)	489 (88)	901 (93)	
Snuser[3]		6 (1.4)	64 (12)	70 (7.2)	
Energy intake, kcal/day	1,007	1,914 (1,572, 2,374)	2,399 (1,912, 2,900)	2,181 (1,733, 2,717)	**<0.001**
Alcohol intake, g/day	1,007	5 (1, 12)	12 (4, 24)	9 (2, 19)	**<0.001**
BMI, kg/m^2	1,000	25.9 (23.1, 28.8)	27.1 (24.6, 29.3)	26.5 (24.1, 29.3)	**<0.001**
Physical activity, min/week	1,015	135 (0, 300)	105 (0, 360)	105 (0, 300)	0.354
Recent antibiotic use, n (%)	964	69 (16)	67 (12)	136 (14)	0.097
WCRF/AICR score, points	943	2.5 (2.0, 3.0)	2.3 (1.8, 2.8)	2.5 (2.0, 3.0)	**<0.001**

[1]Values are median (IQR) for continuous variables and n (%) for categorical variables.
[2]P-values are derived from Wilcoxon rank sum and Pearson`s Chi-squared testing.
[3]To be defined as a snuser one had to be a regular or occasional user or having quit consumption within the last ten years.
Abbreviations: AICR; American Institute of Cancer Research, BMI; Body mass index, CRC; colorectal cancer, g; gram, n; number, WCRF; World Cancer Research Fund

Sex and colorectal lesions

Table 2 shows the associations between sex and colonoscopy findings. Compared to women, men were more likely to present with non-advanced neoplastic lesions and advanced lesions, with odds ratios (ORs) of 1.55 (95% confidence intervals (CI) 1.05, 2.29) and 1.47 (95% CI 1.12, 1.92), respectively. Additional adjustment for lifestyle and demographic factors only modestly attenuated the effect estimates (ORs of 1.50 (95% CI 1.00, 2.26) and 1.46 (95% CI 1.10, 1.93), respectively).

Table 2. Odds ratios (ORs) and 95% confidence intervals (CIs) for presence of non-advanced neoplastic lesions[1] and advanced lesions[2] relative to controls by sex (n=1,034)[3].

	No neoplasia (n=450)	Non-advanced neoplastic lesions (n=142)			Advanced lesions (n=442)		
	n	n	OR (95% CI)	p-value	n	OR (95% CI)	p-value
Female	221	55	Ref.		176	Ref.	
Male							
Model 1	229	87	1.55 (1.05, 2.29)	**0.028**	266	1.47 (1.12, 1.92)	**0.005**
Model 2	229	87	1.50 (1.00, 2.26)	0.052	266	1.46 (1.10, 1.93)	**0.009**

[1]Includes any adenoma (adenomatous polyp) not fulfilling the criteria of being advanced.
[2]Includes advanced adenoma, defined as any adenoma with either villous histology (≥25% villous components), high-grade dysplasia or polyp size greater than or equal to 10 mm; advanced serrated lesions, defined as any serrated lesions with size ≥ 10 mm or dysplasia; and colorectal cancer, defined as presence of adenocarcinoma arising from the colon or rectum.

[3]Odds ratios (ORs) and 95% confidence intervals (CIs) are obtained from multinomial logistic regression analyses adjusting for the following covariates: Model 1: age (continuous) and screening centre (Moss, Bærum); model 2: model 1 covariates, employment status (employed, retired, other), marital status (not married/non-cohabiting, married/cohabiting), smoking status (never smoked, ever smoked) and the WCRF/AICR score (continuous).

Sex and gut microbial features

Among the 1,034 included participants, the mean (SD) number of paired-end reads was 13,030,984 (3,883,470). A total of 2,756 bacterial species were identified, with a mean (SD) of 239 (68) species per sample. The mean (SD) of species per sample was 241 (66) and 237 (69) in men and women, respectively.

<u>α- and β-diversity</u>

Associations of sex with α- and β-diversity are illustrated in Figure 1A-B. There were no associations between sex and the two α-diversity indices (neither Shannon nor the Inverse Simpson index, Figure 1A). However, notable differences in β-diversity were observed between the sexes both in the control group (R2=0.004, p=0.002, Supplementary Figure 1) and the population as a whole (R2=0.003, p=0.001, Figure 1B), which were attenuated, but remained statistically significant after adjusting for lifestyle and demographic factors (R2=0.002, p=0.001).



Figure 1: Differences in α-diversity (A), β-diversity (B) and bacterial species abundance (C) between women and men. A) Within-sample diversity for the two indices Inverse Simpson (left) and Shannon (right) in women and men. B) Principal coordinates analysis (PcoA) plot of the Bray-Curtis dissimilarity index between women and men. C) Differentially abundant bacterial species comparing women and men. Effect estimates are presented as log2FoldChange (Log2FC) with 95% confidence intervals (CI). Species were selected for visualisation based on BH-adjusted p-values <0.05. Features shown in red were significantly more abundant in men, while those in blue were significantly less abundant. All analyses were adjusted for age (continuous), screening centre (Moss, Bærum), employment status (employed, retired, other), marital status (not married/non-cohabiting, married/cohabiting), smoking status (never smoked, ever smoked), and the WCRF/AICR score (continuous).

<u>Differentially abundant bacteria and functions</u>

356 In total, 52 bacterial species were differentially abundant between women and men. Of these, 32
357 (62%) species remained statistically significant after adjusting for lifestyle and demographic
358 factors (Figure 1C, Supplementary Data 1). Nineteen were more abundant in men and 13 in
359 women. The strongest associations with male sex were observed for *Paraprevotella clara*,
360 *Bifidobacterium adolescentis*, *Phocaeicola vulgatus*, and *Alistipes putredinis*. In contrast, the
361 species most strongly associated with female sex were *Eggerthella lenta* and *Streptococcus*
362 *thermophilus*. At the functional level, 174 showed differential abundance between the sexes. Of
363 these, 99 (57%) remained statistically significant after adjusting for lifestyle and demographic
364 factors (Supplementary Figure 2, Supplementary Data 2), with 58 functions more abundant in
365 men and 41 in women. In men, the most enriched molecular functions included hyaluronic acid
366 binding, cytidylyltransferase activity, serine-type carboxypeptidase activity, inositol-3-phosphate
367 synthase activity, pyroglutamyl-peptidase activity, and cysteine-type endopeptidase activity.
368 Enriched biological processes in men included the negative regulation of fatty acid biosynthetic
369 processes, uroporphyrinogen III biosynthetic processes, and inositol biosynthetic processes. In
370 women, the most enriched molecular functions were guanidinobutyrase activity, N-
371 methylhydantoinase (ATP-hydrolyzing) activity, and protein-macromolecule adaptor activity.
372 Enriched biological processes in women included protein glycosylation and nickel cation
373 transport, while the Smc5-Smc6 complex was the most enriched cellular component.



Figure 2. Differences in α-diversity (A), β-diversity (B-C) and abundance of bacterial species (D) between colonoscopy groups among women and men. A) Within sample diversity for the two indices Inverse Simpson (left) and Shannon (right) for the colonoscopy groups, no neoplasia (nn), non-advanced neoplastic lesions (nanl) and advanced colorectal lesions (al) in women and men. B-C) Principal coordinates analysis (PCoA) plot of the Bray Curtis dissimilarity index between colonoscopy groups in women (B) and men (C). D) Differentially abundant bacterial species across colonoscopy groups among women and men. Effect estimates comparing individuals with advanced colorectal lesions to those with no neoplasia are presented as log2FoldChange (log2FC) with 95% confidence intervals (CI). Bacterial species were selected for visualisation based on a BH-adjusted p-value of <0.2 in either sex. Triangle indicates significant interaction term (sex and bacterial abundance) tested in a multinomial logistic regression model (p<0.05). All analyses were adjusted for age (continuous), screening centre (Moss, Bærum), employment status (employed, retired, other), marital status (not married/non-cohabiting, married/cohabiting), smoking status (never smoked, ever smoked), and the WCRF/AICR score (continuous). Abbreviations: *Oscillospiraceae* bacterium Marse…; *Oscillospiraceae* bacterium Marseille-Q3528, sign; significant, ns; non-significant.

Potential interactions between sex, the gut microbiome, and colorectal lesions

Interactions between sex, the gut microbiome, and colorectal lesions were explored to answer two questions: 1) whether the gut microbiome *mediated* the relationship between sex and

392 colorectal lesions, and 2) whether the association between the gut microbiome and colorectal
393 lesions differed by sex (*effect modification*).

394 The gut microbiome as a potential mediator

395 Based on output from differential abundance analyses, two distinct sex-associated microbial
396 scores were developed: One based on a minimally adjusted model (n=37 bacterial species) and
397 another based on a fully adjusted model (n=27 bacterial species). These scores were
398 subsequently used in causal mediation analyses to examine the potential mediating role of sex-
399 related bacteria in colorectal carcinogenesis (see Supplementary Tables 2-3 for species
400 significantly associated with sex in each model). Although neither model yielded statistically
401 significant results, the fully adjusted model showed a modest trend toward a mediation effect
402 (Supplementary Table 4). The total effect of sex on colorectal lesions was 0.09 (95% CI: 0.03–
403 0.14), with an average direct effect (ADE) of 0.08 (95% CI: 0.02–0.13) and an average causal
404 mediation effect (ACME) of 0.01 (95% CI: -0.00–0.02). Overall, the proportion mediated was 10%
405 (95% CI: -2%–39%), which was further supported by a nested counterfactual approach, also
406 estimating a mediated proportion of 10% (Supplementary Table 4).

407 Sex as an effect modifier

408 To evaluate whether the association between the gut microbiome and colorectal lesions differed
409 by sex, sex-stratified analyses were performed for the following microbial measures: 1) α-
410 diversity, 2) β-diversity, and 3) taxonomic and functional profiles. For all measures, notable sex
411 differences were observed. Among women, significant differences in both α- and β-diversity were
412 identified between colonoscopy groups (Figure 2A-B). Women with non-advanced neoplastic
413 lesions had lower α-diversity compared to those without findings, while women with advanced
414 lesions had higher α-diversity levels ($p<0.05$ for all comparisons, Figure 2A). Additionally, distinct
415 separation among colonoscopy groups was observed in the PCoA plot ($R^2=0.006$, $p=0.007$,
416 Figure 2B). Conversely, no significant differences in α- or β-diversity were observed across
417 colonoscopy groups in men (Figure 2A and C). Interaction tests performed using the entire

418 dataset yielded p-values of 0.066, 0.171, and 0.530 for the Shannon, Inverse Simpson, and Bray-
419 Curtis indices, respectively. Analyses comparing advanced serrated lesions with controls yielded
420 consistent results with our overall findings (Supplementary Figure 3). Significant results remained
421 when excluding serrated lesions from the advanced lesion group.
422 For bacterial and function abundance, a sex-specific pattern emerged when comparing the most
423 extreme colonoscopy groups (no neoplasia vs. advanced lesions). In women, 13 bacteria and 17
424 functions were differentially abundant between groups, whereas four bacteria and 12 functions
425 were differentially abundant in men (Figure 2D, Supplementary Figure 4). Among the identified
426 species, five (*GGB52130 SGB14966*, *Enterocloster bolteae, Faecalibacterium prausnitzii,*
427 *GGB51647 SGB4348,* and *Flavonifractor plautii*) were confirmed to be sex-specific in multinomial
428 logistic regression analyses (p-values for interaction terms <0.05). Notably, *E. lenta* and
429 *Hungatella hathewayi* were inversely associated with advanced lesions regardless of sex. Among
430 the differentially abundant functions, six were confirmed to be sex-specific in multinomial logistic
431 regression analyses (p-values for interaction terms <0.05). The six functions included one related
432 to biological processes (regulation of GTPase activity), and five related to molecular functions
433 (1,4-alpha-glucan branching enzyme activity, dipeptidyl-peptidase activity, 1,4-alpha-glucan
434 branching enzyme activity (using a glycosylated glycogenin as primer for glycogen synthesis),
435 hydrolase activity, acting on acid anhydrides, and hydrolase activity, acting on ester bonds).

436 ## Discussion

437 Numerous large studies have examined the gut microbiome as a potential biomarker for CRC,
438 but often overlook the importance of sex (48, 98-100). Our study, including metagenomes from
439 >1000 CRC screening participants, suggests that sex may serve as an effect modifier in the
440 relationship between the gut microbiome and CRC development. Specifically, microbial α- and β-
441 diversity varied across lesion subtypes in women, while no such differences were observed in
442 men. Interaction analyses further identified sex-specific bacterial and functional profiles linked to
443 presence of colorectal lesions. This highlights the importance of considering sex in microbial
444 biomarker studies, potentially extending to other conditions beyond CRC.

445 Our CRCbiome study included FIT-positive participants recruited from the large Norwegian
446 screening trial BCSN. Consistent with previous studies (21), including results from BCSN (15, 71),
447 we found that men had a significantly higher odds of presenting with both non-advanced
448 neoplastic lesions (55%) and advanced lesions (47%) at follow-up colonoscopy. The higher
449 occurrence of lesions in men could be partially attributed to FIT being less efficient in women. To
450 optimise performance across sexes, sex-specific FIT thresholds have been suggested (23).
451 However, adjusting FIT thresholds is not straightforward (20, 23, 101), highlighting the need for
452 complementary strategies

453 The presence of advanced lesions is strongly linked to modifiable risk factors (67, 102-108), as
454 also documented in our cohorts (81, 92, 109-111). This has led to the hypothesis that the
455 association between male sex and CRC risk, at least in part, is caused by these factors (40, 65,
456 112). In a large German screening cohort (n=16,000 (113)), known risk factors were found to
457 explain about half (47%) of the excess risk of advanced neoplasia among men, yet a substantial
458 portion remained unexplained. Similarly, in our study, most of the male excess risk remained
459 unexplained (>90%). These observations suggest that modifiable risk factors alone are
460 insufficient to explain the sex gap in CRC risk.

461 As for differences in the microbial profile between women and men, our study suggests that these
462 disparities are not merely attributable to differences in exposure profiles. After adjusting for major
463 contributors to microbial variation, a large part of the sex-microbiome associations remained,
464 suggesting that intrinsic factors are influential. In support of this, the gut microbiome of women
465 and men has been found to diverge during puberty – a period marked by significant hormonal
466 changes (114). In a meta-analysis by Zhang *et al.* (115), including Asian and European cohorts
467 across a wide age range, sex-specific differences in β-diversity were observed. Interestingly, while
468 no sex-related differences were observed in the microbiomes of prepubescent children, notable
469 differences emerged in younger adults before attenuating in individuals over the age of 50.
470 Our results of distinct sex-specific microbial profiles are in line with previous literature (56, 115-
471 118), including investigations within CRCbiome, suggesting the presence of sex-specific microbial
472 profiles linked to alcohol consumption (92). In the present study, we identified thirty-two bacterial
473 species that were differentially abundant between men and women. We have previously reported
474 that men in CRCbiome have a higher abundance of *P. succinatutens* (119) and have identified
475 CRC associations for bacteria of the *Phascolarctobacterium* genus across populations (119-121).
476 We also found that *B. adolescentis* levels were higher in men. Interestingly, this species has
477 previously been found to be elevated in older male CRC patients (122) and has been proposed
478 as a probiotic due to its pro-androgenic activity (123). In line with previous reports, we observed
479 a higher abundance of *E. lenta* and *G. pamelae* in women (115, 116). Both species potentially
480 play a role in host physiology and hormonal homeostasis via corticoid conversion to progestin
481 (124). *E. lenta* has also been reported as being increased in women with premature ovarian
482 insufficiency (125). The hormone-related *E. lenta* was the only species identified as both sex-
483 specific and linked to the presence of lesions. A potential influence of sex hormones such as
484 oestrogen and testosterone on the gut microbiome, which may, in turn, interact with CRC risk,
485 was recently explored (40). For instance, oestrogens are known to exhibit anti-inflammatory
486 properties, potentially modulating the gut environment, and influencing cancer risk differently in

487 men and women, whereas androgens seem to exacerbate cancer development. Indeed, the role
488 of sex hormones in CRC development has been demonstrated in mice (59, 126).
489 We found that the associations between the gut microbiome and colorectal lesions differed
490 between men and women. Specifically, women showed significant differences in both α- and β-
491 diversity across colonoscopy groups, whereas no such differences were observed in men. Some
492 studies have investigated sex-based differences in the microbiome within a CRC context (56, 58,
493 61, 62). These studies typically have a small sample size (N < 90) (58, 61) or include only genus-
494 level taxonomic resolution (56, 58). Nonetheless, they demonstrate that men and women display
495 distinct microbial profiles not only among healthy controls but also among individuals with non-
496 advanced neoplastic lesions and CRC. Interestingly, Liao *et al.* (58) also observed sex differences
497 and larger variations in women during CRC development compared to men.
498 We further found that the bacteria *F. plautii*, and *E. bolteae* were associated with advanced lesions
499 in a sex-specific manner, being lower in female controls. Several studies have found an increase
500 in *F. plautii* in CRC (127, 128), especially young-onset CRC (129). This species has also been
501 found to be more prevalent in tubular adenomas than in sessile serrated adenomas (130). *E.*
502 *bolteae* (formerly *Clostridium bolteae*), an opportunistic pathogen in the human gut (131),
503 comprise strains with potentially varying effects on the immune system. When administered
504 intrarectally, for example, *E. boltae* strains were capable of both alleviating and exacerbating
505 diarrhoea symptoms in mice colitis models (132). Finally, *F. prausnitzii* was increased in advanced
506 lesions compared to controls in women. Although this species is believed to exert anti-
507 inflammatory effects in the gastrointestinal tract (133), research has identified this species as a
508 complex group consisting of 84 strains, each with diverse functional traits, suggesting a
509 multifaceted role in human health (134).
510 Our results, showing that microbial associations with colorectal lesions in general are more
511 pronounced in women, suggest that microbial biomarkers might be more effective in women than
512 men. This raises the possibility that incorporating a microbial marker alongside FIT could improve

513 diagnostic accuracy for women, potentially overcoming the current sex-related limitations of the
514 test.
515 A major strength of our study is the extensive microbiome dataset, combined with clinically verified
516 outcome data, enabling a thorough assessment of screening-relevant outcomes with minimal risk
517 of misclassification. Additionally, access to detailed lifestyle and demographic data enabled robust
518 covariate adjustments, distinguishing our study from most prior investigations on this topic (56,
519 58, 63). However, several limitations must be acknowledged. First, the cross-sectional design
520 prevents causal interpretations. Second, participation required enrolment in two consecutive
521 studies: first, the BCSN, followed by CRCbiome, potentially introducing selection bias. In the
522 BCSN, certain discrepancies existed in participant characteristics between men and women. For
523 men, non-participation was linked to younger age and not living with a partner, whereas for
524 women, it was associated with living farther from the screening centre (135, 136). Third, while our
525 comprehensive covariate adjustments strengthen the study, the possibility of residual
526 confounding cannot be ruled out.
527 To conclude, in this FIT-positive CRC screening population, we observe sex-specific microbial
528 patterns and differences in screening findings. Further, our analyses suggest that sex modifies
529 the association between the microbiome and CRC. Notably, we observed significant microbial
530 differences across lesion subtypes in women, but not in men. Additionally, clear sex-specific
531 distinctions were observed in the bacterial and functional profiles linked to colorectal lesions. Our
532 results underscore the importance of considering sex in research investigating the gut
533 microbiome-colorectal lesion axis, with implications for biomarker discovery and tailoring
534 personalised CRC prevention, detection, and therapy.

Acknowledgements

We would like to acknowledge Jan Inge Nordby for his contribution to sample preparation and lab work. Library preparation and sequencing were performed at the FIMM Technology Centre supported by HiLIFE and Biocenter Finland. We would especially like to thank Harri A. Kangas, and Pekka J. Ellonen. Finally, we want to thank our project coordinator Maja Sigerseth Jacobsen.

Data availability

Data from the CRCbiome project have been deposited in the database Federated EGA under accession code EGAS50000000170. Due to the sensitive nature of the data derived from human subjects, including personal health information, analyses and sharing of data from this project must comply with the General Data Protection Regulation (GDPR). How to get access to the data is described here: https://www.mn.uio.no/bils/english/groups/rounge-group/crcbiome/. R-scripts used in this study are available at: https://github.com/Rounge-lab/sex-differences

Author contributions

TBR and PB were responsible for the conception and design of the study. ASK, CBJ, and EB analysed the data. VB performed the sample preparation and lab work. ASK, CBJ, EB, EA, EB, PB, and TBR interpreted the data. ASK and CBJ drafted the manuscript. All authors have revised, commented on, and approved the final submitted manuscript.

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.

2. Global Cancer Observatory. Cancer Tomorrow | IARC - https://gco.iarc.who.int/tomorrow [Internet]. [Available from: https://gco.iarc.fr/tomorrow/en/dataviz/trends?types=0_1&sexes=1_2&mode=population&group_populations=0&multiple_populations=1&multiple_cancers=1&cancers=8_41&populations=900&apc=cat_ca20v1.5_ca23v-1.5&group_cancers=1.

561 3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
562 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
563 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

564 4. Baraibar I, Ros J, Saoudi N, Salva F, Garcia A, Castells MR, et al. Sex and gender
565 perspectives in colorectal cancer. ESMO Open. 2023;8(2):101204.

566 5. Atkin W, Wooldrage K, Parkin DM, Kralj-Hans I, MacRae E, Shah U, et al. Long term
567 effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible
568 Sigmoidoscopy Screening randomised controlled trial. Lancet. 2017;389(10076):1299-311.

569 6. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al.
570 Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med.
571 2012;366(25):2345-57.

572 7. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-only
573 sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized
574 Controlled Trial--SCORE. J Natl Cancer Inst. 2011;103(17):1310-22.

575 8. Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Effect of flexible
576 sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial.
577 JAMA. 2014;312(6):606-15.

578 9. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing
579 mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer
580 Control Study. N Engl J Med. 1993;328(19):1365-71.

581 10. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of
582 screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-71.

583 11. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal
584 occult blood screening for colorectal cancer. Br J Surg. 2008;95(8):1029-36.

585 12. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al.
586 Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet.
587 1996;348(9040):1472-7.

588 13. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal
589 cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637-49.

590 14. Council of the European Union. Council Recommendation on strengthening prevention
591 through early detection: A new EU approach on cancer screening replacing Council
592 Recommendation 2003/878/EC. Off J Eur Union. 2022;100:1-10.

593 15. Randel KR, Botteri E, de Lange T, Schult AL, Eskeland SL, El-Safadi B, et al. Performance
594 of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity
595 Thresholds. Aliment Pharmacol Ther. 2025;61(1):122-31.

596 16. Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for Colorectal Cancer
597 Screening. Gastroenterology. 2020;158(2):418-32.

598 17. Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical
599 faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer.
600 2011;104(11):1779-85.

601 18. Hultcrantz R. Aspects of colorectal cancer screening, methods, age and gender. J Intern
602 Med. 2021;289(4):493-507.

603 19. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing.
604 Am J Gastroenterol. 2010;105(11):2457-64.

605 20. Brenner H, Qian J, Werner S. Variation of diagnostic performance of fecal
606 immunochemical testing for hemoglobin by sex and age: results from a large screening cohort.
607 Clin Epidemiol. 2018;10:381-9.

608 21. White A, Ironmonger L, Steele RJC, Ormiston-Smith N, Crawford C, Seims A. A review of
609 sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis,
610 cancer stage and survival in the UK. BMC cancer. 2018;18(1):906.

611 22. Njor SH, Rasmussen M, Friis-Hansen L, Andersen B. Varying fecal immunochemical test
612 screening cutoffs by age and gender: a way to increase detection rates and reduce the number
613 of colonoscopies. Gastrointest Endosc. 2022;95(3):540-9.

614 23. Grobbee EJ, Wieten E, Hansen BE, Stoop EM, de Wijkerslooth TR, Lansdorp-Vogelaar I,
615 et al. Fecal immunochemical test-based colorectal cancer screening: The gender dilemma. United
616 European Gastroenterol J. 2017;5(3):448-54.

617 24. Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities
618 in colorectal cancer risk. World J Gastroenterol. 2015;21(17):5167-75.

619 25. Streett SE. Endoscopic colorectal cancer screening in women: can we do better?
620 Gastrointest Endosc. 2007;65(7):1047-9.

621 26. Witte TN, Enns R. The difficult colonoscopy. Can J Gastroenterol. 2007;21(8):487-90.

622 27. Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Long-Term
623 Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in
624 Women and Men: A Randomized Trial. Ann Intern Med. 2018;168(11):775-82.

625 28. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-
626 12.

627 29. DeWeerdt S. Microbiome: Microbial mystery. Nature. 2015;521(7551):S10-1.

628 30. Garrett WS. The gut microbiota and colon cancer. Science. 2019;364(6446):1133-5.

629 31. Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. Nat Rev
630 Clin Oncol. 2023;20(7):429-52.

631 32. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical
632 applications. Nat Rev Gastroenterol Hepatol. 2019;16(11):690-704.

633 33. Janney A, Powrie F, Mann EH. Host-microbiota maladaptation in colorectal cancer.
634 Nature. 2020;585(7826):509-17.

635 34. Xing C, Du Y, Duan T, Nim K, Chu J, Wang HY, et al. Interaction between microbiota and
636 immunity and its implication in colorectal cancer. Front Immunol. 2022;13:963819.

637 35. Chen Y, Chen YX. Microbiota-Associated Metabolites and Related Immunoregulation in
638 Colorectal Cancer. Cancers (Basel). 2021;13(16):4054.

639 36. Zheng DP, Liwinski T, Elinav E. Interaction between microbiota and immunity in health
640 and disease. Cell Res. 2020;30(6):492-506.

641 37. Park CH, Eun CS, Han DS. Intestinal microbiota, chronic inflammation, and colorectal
642 cancer. Intest Res. 2018;16(3):338-45.

643 38. Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The Genus Alistipes: Gut
644 Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health. Front Immunol.
645 2020;11:906.

646 39. Sanchez-Alcoholado L, Ordonez R, Otero A, Plaza-Andrade I, Laborda-Illanes A, Medina
647 JA, et al. Gut Microbiota-Mediated Inflammation and Gut Permeability in Patients with Obesity
648 and Colorectal Cancer. Int J Mol Sci. 2020;21(18).

649 40. Wu Z, Huang Y, Zhang R, Zheng C, You F, Wang M, et al. Sex differences in colorectal
650 cancer: with a focus on sex hormone-gut microbiome axis. Cell Commun Signal. 2024;22(1):167.

651 41. Rodriguez-Santiago Y, Garay-Canales CA, Nava-Castro KE, Morales-Montor J. Sexual
652 dimorphism in colorectal cancer: molecular mechanisms and treatment strategies. Biol Sex Differ.
653 2024;15(1):48.

654 42. Zhou YL, Hong J. Gut microbiota: Guardians of the female gut health. Cancer Cell.
655 2023;41(8):1392-4.

656 43. Cheng WT, Kantilal HK, Davamani F. The Mechanism of Bacteroides fragilis Toxin
657 Contributes to Colon Cancer Formation. Malays J Med Sci. 2020;27(4):9-21.

658 44. Spigaglia P, Barbanti F, Germinario EAP, Criscuolo EM, Bruno G, Sanchez-Mete L, et al.
659 Comparison of microbiological profile of enterotoxigenic Bacteroides fragilis (ETBF) isolates from
660 subjects with colorectal cancer (CRC) or intestinal pre-cancerous lesions versus healthy
661 individuals and evaluation of environmental factors involved in intestinal dysbiosis. Anaerobe.
662 2023;82:102757.

663 45. Arima K, Zhong R, Ugai T, Zhao M, Haruki K, Akimoto N, et al. Western-Style Diet, pks
664 Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses From Two Large Prospective
665 Cohort Studies. Gastroenterology. 2022;163(4):862-74.

666 46. Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM,
667 Nomburg J, et al. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli.
668 Nature. 2020;580(7802):269-73.

669 47. Sengupta S, Muir JG, Gibson PR. Does butyrate protect from colorectal cancer? J
670 Gastroenterol Hepatol. 2006;21(1 Pt 2):209-18.

671 48. Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. Meta-analysis of fecal
672 metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med.
673 2019;25(4):679-89.

674 49. Chen D, Jin D, Huang S, Wu J, Xu M, Liu T, et al. Clostridium butyricum, a butyrate-
675 producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and
676 gut microbiota. Cancer Lett. 2020;469:456-67.

677 50. Zwezerijnen-Jiwa FH, Sivov H, Paizs P, Zafeiropoulou K, Kinross J. A systematic review
678 of microbiome-derived biomarkers for early colorectal cancer detection. Neoplasia.
679 2023;36:100868.

680 51. Fusco W, Bricca L, Kaitsas F, Tartaglia MF, Venturini I, Rugge M, et al. Gut microbiota in
681 colorectal cancer: From pathogenesis to clinic. Best Pract Res Clin Gastroenterol.
682 2024;72:101941.

683 52. Valeri F, Endres K. How biological sex of the host shapes its gut microbiota. Front
684 Neuroendocrinol. 2021;61:100912.

685 53. Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, et al. The microgenderome
686 revealed: sex differences in bidirectional interactions between the microbiota, hormones,
687 immunity and disease susceptibility. Semin Immunopathol. 2019;41(2):265-75.

688 54. Yoon K, Kim N. Roles of Sex Hormones and Gender in the Gut Microbiota. J
689 Neurogastroenterol Motil. 2021;27(3):314-25.

690 55. Thackray VG. Sex, Microbes, and Polycystic Ovary Syndrome. Trends Endocrinol Metab.
691 2019;30(1):54-65.

692 56. Yang X, Li P, Qu Z, Zhuang J, Wu Y, Wu W, et al. Gut bacteria and sex differences in
693 colorectal cancer. J Med Microbiol. 2023;72(6).

694 57. Wang L, Tu YX, Chen L, Zhang Y, Pan XL, Yang SQ, et al. Male-Biased Gut Microbiome
695 and Metabolites Aggravate Colorectal Cancer Development. Adv Sci (Weinh).
696 2023;10(25):e2206238.

697 58. Liao H, Li C, Ai Y, Kou Y. Gut microbiome is more stable in males than in females during
698 the development of colorectal cancer. J Appl Microbiol. 2021;131(1):435-48.

699 59. Li Q, Chan H, Liu WX, Liu CA, Zhou Y, Huang D, et al. Carnobacterium maltaromaticum
700 boosts intestinal vitamin D production to suppress colorectal cancer in female mice. Cancer Cell.
701 2023;41(8):1450-65 e8.

702 60. Song CH, Kim N, Nam RH, Choi SI, Yu JE, Nho H, et al. Changes in Microbial Community
703 Composition Related to Sex and Colon Cancer by Nrf2 Knockout. Front Cell Infect Microbiol.
704 2021;11:636808.

705 61. Song CH, Kim N, Nam RH, Choi SI, Jang JY, Kim EH, et al. The Possible Preventative
706 Role of Lactate- and Butyrate-Producing Bacteria in Colorectal Carcinogenesis. Gut Liver.
707 2024;18(4):654-66.

708 62. Yu S, Chu J, Wu Y, Zhuang J, Qu Z, Song Y, et al. Third-generation PacBio sequencing
709 to explore gut bacteria and gender in colorectal cancer. Microb Pathog. 2024;192:106684.

710 63. Lattanzi G, Perillo F, Diaz-Basabe A, Caridi B, Amoroso C, Baeri A, et al. Estrogen-related
711 differences in antitumor immunity and gut microbiome contribute to sexual dimorphism of
712 colorectal cancer. Oncoimmunology. 2024;13(1):2425125.

713 64. Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual Dimorphism in Colon
714 Cancer. Front Oncol. 2020;10:607909.

715 65. Chang YM, Kang YR, Lee YG, Sung MK. Sex differences in colonic gene expression and
716 fecal microbiota composition in a mouse model of obesity-associated colorectal cancer. Scientific
717 reports. 2024;14(1):3576.

718 66. World Cancer Research Fund/American Institute for Cancer Research. Continuous
719 update project report. Food, nutrition, physical activity, and the prevention of colorectal cancer.
720 American Institute for Cancer Research Washington (DC); 2011.

721 67. Wild CP, Weiderpass E, Stewart BW. World cancer report. 2020.

722 68. Song M, Chan AT. Environmental Factors, Gut Microbiota, and Colorectal Cancer
723 Prevention. Clin Gastroenterol Hepatol. 2019;17(2):275-89.

724 69. Song M, Chan AT, Sun J. Influence of the Gut Microbiome, Diet, and Environment on Risk
725 of Colorectal Cancer. Gastroenterology. 2020;158(2):322-40.

726 70. Kvaerner AS, Birkeland E, Bucher-Johannessen C, Vinberg E, Nordby JI, Kangas H, et
727 al. The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the
728 gut microbiome in colorectal cancer screening participants. BMC cancer. 2020.

729 71. Randel KR, Schult AL, Botteri E, Hoff G, Bretthauer M, Ursin G, et al. Colorectal Cancer
730 Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results
731 From a Randomized Trial. Gastroenterology. 2021;160(4):1085-96 e5.

732 72. Andersen LF, Solvoll K, Johansson LR, Salminen I, Aro A, Drevon CA. Evaluation of a
733 food frequency questionnaire with weighed records, fatty acids, and alpha-tocopherol in adipose
734 tissue and serum. Am J Epidemiol. 1999;150(1):75-87.

735 73. Andersen LF, Tomten H, Haggarty P, Lovo A, Hustvedt BE. Validation of energy intake
736 estimated from a food frequency questionnaire: a doubly labelled water study. Eur J Clin Nutr.
737 2003;57(2):279-84.

738 74. Andersen LF, Veierod MB, Johansson L, Sakhi A, Solvoll K, Drevon CA. Evaluation of
739 three dietary assessment methods and serum biomarkers as measures of fruit and vegetable
740 intake, using the method of triads. Br J Nutr. 2005;93(4):519-27.

741 75. Carlsen MH, Lillegaard IT, Karlsen A, Blomhoff R, Drevon CA, Andersen LF. Evaluation
742 of energy and dietary intake estimates from a food frequency questionnaire using independent
743 energy expenditure measurement and weighed food records. Nutr J. 2010;9(1):37.

744 76. Brunvoll SH, Thune I, Frydenberg H, Flote VG, Bertheussen GF, Schlichting E, et al.
745 Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a
746 biomarker in breast cancer patients during treatment. Nutr J. 2018;17(1):94.

747 77. Nes M, Frost Andersen L, Solvoll K, Sandstad B, Hustvedt BE, Lovo A, et al. Accuracy of
748 a quantitative food frequency questionnaire applied in elderly Norwegian women. Eur J Clin Nutr.
749 1992;46(11):809-21.

750 78. Norwegian Food Safety Authority. Norwegian Food Composition Database 2019
751 [Internet]. 2019 [cited 2025 20.02]. Available from: www.matvaretabellen.no.

752 79. Shams-White MM, Brockton NT, Mitrou P, Romaguera D, Brown S, Bender A, et al.
753 Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer Research
754 (WCRF/AICR) Cancer Prevention Recommendations: A Standardized Scoring System. Nutrients.
755 2019;11(7).

756 80. Shams-White MM, Romaguera D, Mitrou P, Reedy J, Bender A, Brockton NT. Further
757 Guidance in Implementing the Standardized 2018 World Cancer Research Fund/American
758 Institute for Cancer Research (WCRF/AICR) Score. Cancer Epidemiology Biomarkers &
759 Prevention. 2020;29(5):889-94.

760 81. Kvaerner AS, Andersen AR, Henriksen HB, Knudsen MD, Johansen AMW, Hjartaker A,
761 et al. Associations of the 2018 World Cancer Research Fund/American Institute of Cancer
762 Research (WCRF/AICR) cancer prevention recommendations with stages of colorectal
763 carcinogenesis. Cancer Med. 2023;12(13):14806-19.

764 82. Istvan P, Birkeland E, Avershina E, Kvaerner AS, Bemanian V, de Vos W, et al. Exploring
765 the gut virome in fecal immunochemical test stool samples reveals novel associations with
766 lifestyle in a large population-based study. medRxiv. 2023:2023.08. 24.23294548.

767 83. Rounge TB, Meisal R, Nordby JI, Ambur OH, de Lange T, Hoff G. Evaluating gut
768 microbiota profiles from archived fecal samples. BMC Gastroenterol. 2018;18(1):171.

769 84. Blanco-Miguez A, Beghini F, Cumbo F, McIver LJ, Thompson KN, Zolfo M, et al. Extending
770 and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn
771 4. Nat Biotechnol. 2023;41(11):1633-44.

772 85. Beghini F, McIver LJ, Blanco-Miguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating
773 taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery
774 3. Elife. 2021;10.

775 86. Wang Y, Wang Q, Huang H, Huang W, Chen Y, McGarvey PB, et al. A crowdsourcing
776 open platform for literature curation in UniProt. PLoS Biol. 2021;19(12):e3001464.

777 87. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology:
778 tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-9.

88. Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, et al. Gene Ontology Consortium. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224(1).

89. Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. Journal of statistical software. 2011;45:1-67.

90. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin P, O'Hara R, et al. Vegan: community ecology package. Ordination methods, diversity analysis and other functions for community and vegetation ecologists. 2015:2.3-1.

91. Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol. 2021;17(11):e1009442.

92. Kvaerner AS, Birkeland E, Avershina E, Botteri E, Bucher-Johannessen C, Dines Knudsen M, et al. The association between alcohol consumption and colorectal carcinogenesis is partially mediated by the gut microbiome. medRxiv. 2024:2024.10. 17.24315656.

93. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal Mediation Analysis. Journal of Statistical Software. 2014;59(5).

94. Steen J, Loeys T, Moerkerke B, Vansteelandt S. medflex: An R Package for Flexible Mediation Analysis using Natural Effect Models. Journal of Statistical Software. 2017;76(11):1-46.

95. Wickham H, Averick M, Bryan J, Chang W, McGowan LDA, François R, et al. Welcome to the Tidyverse. Journal of open source software. 2019;4(43):1686.

96. Kassambara A. rstatix: Pipe-friendly framework for basic statistical tests. R package version 06 0. 2020.

97. Venables WN, Ripley BD. Modern applied statistics with S-PLUS: Springer Science & Business Media; 2013.

98. Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med. 2019;25(4):667-78.

99. Young C, Wood HM, Fuentes Balaguer A, Bottomley D, Gallop N, Wilkinson L, et al. Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy. Clin Cancer Res. 2021;27(8):2246-54.

100. Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 2019;25(6):968-76.

101. Selby K, Levine EH, Doan C, Gies A, Brenner H, Quesenberry C, et al. Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis. Gastroenterology. 2019;157(6):1494-505.

815 102. World Cancer Research Fund/American Institute for Cancer Research. Diet, nutrition,
816 physical activity and colorectal cancer. Continous Update Project Expert Report 2018; 2018.

817 103. Godos J, Bella F, Torrisi A, Sciacca S, Galvano F, Grosso G. Dietary patterns and risk of
818 colorectal adenoma: a systematic review and meta-analysis of observational studies. J Hum Nutr
819 Diet. 2016;29(6):757-67.

820 104. Erben V, Carr PR, Holleczek B, Stegmaier C, Hoffmeister M, Brenner H. Dietary patterns
821 and risk of advanced colorectal neoplasms: A large population based screening study in
822 Germany. Prev Med. 2018;111:101-9.

823 105. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and
824 adenomatous polyps: a meta-analysis. Gastroenterology. 2008;134(2):388-95.

825 106. Ben Q, Wang L, Liu J, Qian A, Wang Q, Yuan Y. Alcohol drinking and the risk of colorectal
826 adenoma: a dose-response meta-analysis. Eur J Cancer Prev. 2015;24(4):286-95.

827 107. Bailie L, Loughrey MB, Coleman HG. Lifestyle Risk Factors for Serrated Colorectal Polyps:
828 A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(1):92-104.

829 108. He X, Hang D, Wu K, Nayor J, Drew DA, Giovannucci EL, et al. Long-term Risk of
830 Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps.
831 Gastroenterology. 2020;158(4):852-61 e4.

832 109. Kvaerner AS, Birkeland E, Vinberg E, Hoff G, Hjartaker A, Rounge TB, et al. Associations
833 of red and processed meat intake with screen-detected colorectal lesions. Br J Nutr.
834 2023;129(12):2122-32.

835 110. Knudsen MD, Botteri E, Holme O, Hjartaker A, Song M, Thiis-Evensen E, et al. Association
836 between lifestyle and site-specific advanced colorectal lesions in screening with faecal
837 immunochemical test and sigmoidoscopy. Dig Liver Dis. 2021;53(3):353-9.

838 111. Knudsen MD, de Lange T, Botteri E, Nguyen DH, Evensen H, Steen CB, et al. Favorable
839 lifestyle before diagnosis associated with lower risk of screen-detected advanced colorectal
840 neoplasia. WJG. 2016;22(27):6276-86.

841 112. Joo HJ, Lee HS, Jang BI, Kim DB, Kim JH, Park JJ, et al. Sex-specific differences in
842 colorectal cancer: A multicenter retrospective cohort study. Cancer Rep (Hoboken).
843 2023;6(8):e1845.

844 113. Niedermaier T, Heisser T, Gies A, Guo F, Amitay EL, Hoffmeister M, et al. To what extent
845 is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results
846 from a large German screening population. Intl Journal of Cancer. 2021;149(11):1877-86.

847 114. Calcaterra V, Rossi V, Massini G, Regalbuto C, Hruby C, Panelli S, et al. Precocious
848 puberty and microbiota: The role of the sex hormone-gut microbiome axis. Front Endocrinol
849 (Lausanne). 2022;13:1000919.

850 115. Zhang X, Zhong H, Li Y, Shi Z, Ren H, Zhang Z, et al. Sex- and age-related trajectories of
851 the adult human gut microbiota shared across populations of different ethnicities. Nat Aging.
852 2021;1(1):87-100.

853 116. Sinha T, Vich Vila A, Garmaeva S, Jankipersadsing SA, Imhann F, Collij V, et al. Analysis
854 of 1135 gut metagenomes identifies sex-specific resistome profiles. Gut Microbes.
855 2019;10(3):358-66.

856 117. Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level
857 analysis of gut microbiome variation. Science. 2016;352(6285):560-4.

858 118. de la Cuesta-Zuluaga J, Kelley ST, Chen Y, Escobar JS, Mueller NT, Ley RE, et al. Age-
859 and Sex-Dependent Patterns of Gut Microbial Diversity in Human Adults. mSystems. 2019;4(4).

860 119. Bucher-Johannessen C, Senthakumaran T, Avershina E, Birkeland E, Hoff G, Bemanian
861 V, et al. Species-level verification of Phascolarctobacterium association with colorectal cancer.
862 mSystems. 2024;9(10):e0073424.

863 120. Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P, et al.
864 Long-term follow-up of colorectal cancer screening attendees identifies differences in
865 Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing. Front Oncol.
866 2023;13:1183039.

867 121. Senthakumaran T, Moen AEF, Tannaes TM, Endres A, Brackmann SA, Rounge TB, et al.
868 Microbial dynamics with CRC progression: a study of the mucosal microbiota at multiple sites in
869 cancers, adenomatous polyps, and healthy controls. Eur J Clin Microbiol Infect Dis.
870 2023;42(3):305-22.

871 122. Hua H, Sun Y, He X, Chen Y, Teng L, Lu C. Intestinal Microbiota in Colorectal Adenoma-
872 Carcinoma Sequence. Front Med (Lausanne). 2022;9:888340.

873 123. Doden HL, Pollet RM, Mythen SM, Wawrzak Z, Devendran S, Cann I, et al. Structural and
874 biochemical characterization of 20beta-hydroxysteroid dehydrogenase from Bifidobacterium
875 adolescentis strain L2-32. The Journal of biological chemistry. 2019;294(32):12040-53.

876 124. McCurry MD, D'Agostino GD, Walsh JT, Bisanz JE, Zalosnik I, Dong X, et al. Gut bacteria
877 convert glucocorticoids into progestins in the presence of hydrogen gas. Cell. 2024;187(12):2952-
878 68 e13.

879 125. Jiang L, Fei H, Tong J, Zhou J, Zhu J, Jin X, et al. Hormone Replacement Therapy
880 Reverses Gut Microbiome and Serum Metabolome Alterations in Premature Ovarian
881 Insufficiency. Front Endocrinol (Lausanne). 2021;12:794496.

882 126. Song CH, Kim N, Nam RH, Choi SI, Lee HN, Surh YJ. 17beta-Estradiol supplementation
883 changes gut microbiota diversity in intact and colorectal cancer-induced ICR male mice. Scientific
884 reports. 2020;10(1):12283.

885 127. Gupta A, Dhakan DB, Maji A, Saxena R, P KV, Mahajan S, et al. Association of
886 Flavonifractor plautii, a Flavonoid-Degrading Bacterium, with the Gut Microbiome of Colorectal
887 Cancer Patients in India. mSystems. 2019;4(6).

888 128. Qin Y, Tong X, Mei WJ, Cheng Y, Zou Y, Han K, et al. Consistent signatures in the human
889 gut microbiome of old- and young-onset colorectal cancer. Nat Commun. 2024;15(1):3396.

890 129. Yang Y, Du L, Shi D, Kong C, Liu J, Liu G, et al. Dysbiosis of human gut microbiome in
891 young-onset colorectal cancer. Nat Commun. 2021;12(1):6757.

892 130. Lee JWJ, Plichta DR, Asher S, Delsignore M, Jeong T, McGoldrick J, et al. Association of
893 distinct microbial signatures with premalignant colorectal adenomas. Cell Host Microbe.
894 2023;31(5):827-38 e3.

895 131. Sprotte S, Brinks E, Neve H, Franz C. Complete genome sequence of the novel virulent
896 phage PMBT24 infecting Enterocloster bolteae from the human gut. Heliyon. 2024;10(8):e28813.

897 132. Giri R, Hoedt EC, Khushi S, Salim AA, Bergot AS, Schreiber V, et al. Secreted NF-kappaB
898 suppressive microbial metabolites modulate gut inflammation. Cell Rep. 2022;39(2):110646.

899 133. Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii Reduction and
900 Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature.
901 Gastroenterol Res Pract. 2014;2014:872725.

902 134. Bai Z, Zhang N, Jin Y, Chen L, Mao Y, Sun L, et al. Comprehensive analysis of 84
903 Faecalibacterium prausnitzii strains uncovers their genetic diversity, functional characteristics,
904 and potential risks. Front Cell Infect Microbiol. 2022;12:919701.

905 135. Berthelsen M, Berstad P, Randel KR, Hoff G, Natvig E, Holme O, et al. The impact of
906 driving time on participation in colorectal cancer screening with sigmoidoscopy and faecal
907 immunochemical blood test. Cancer Epidemiol. 2022;80:102244.

908 136. Botteri E, Hoff G, Randel KR, Holme O, de Lange T, Bernklev T, et al. Characteristics of
909 nonparticipants in a randomised colorectal cancer screening trial comparing sigmoidoscopy and
910 faecal immunochemical testing. Int J Cancer. 2022;151(3):361-71.
911